Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT719 in Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
NCT06948981Phase 2Recruiting
- Sponsor
- Grit Biotechnology
- Start
- Apr 2025
- Primary completion
- Apr 2028
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GT719 in B-cell non-Hodgkin lymphoma and B cell acute lymphoblastic leukemia (B-ALL), sponsored by Grit Biotechnology. Primary endpoint: Adverse Events at 12 months. Started Apr 2025; status: recruiting.
02
Drugs
GT719
03
Conditions
B-cell non-Hodgkin lymphomaB cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06948981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06948981.